Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tom A Yates

Showing results (11-20 of 49) with videos related to

Pageof 5
Sort By:
BMJ (Clinical Research Ed.)|April 26, 2012
An alternative set of principles for considerationTom A Yates, Carl J Reynolds
Lancet (London, England)|October 19, 2024
Nutritional supplementation for tuberculosis prevention: the RATIONS trialHannah M Rickman, Tom A Yates
The Journal of Infectious Diseases|January 8, 2026
Re: Estimating the Early Transmission Inhibition of New Treatment Regimens for Drug-Resistant TuberculosisTom A Yates, David A Barr
The Lancet. Infectious Diseases|August 27, 2022
Estimating annual risk of infection with Mycobacterium tuberculosisTom A Yates, Palwasha Y Khan
The Lancet. Microbe|March 18, 2025
Primary efficacy endpoints in phase 3 non-inferiority trials to establish new tuberculosis treatment regimens should only include microbiological outcomesTom A Yates, Daniel J Grint
The Journal of Infectious Diseases|November 13, 2014
HIV infection and the transmission of tuberculosisTom A Yates, Ibrahim Abubakar, Frank Tanser
BMJ (Clinical Research Ed.)|October 10, 2025
Priorities in addressing rifampicin resistant TBTom A Yates, Jessica L Potter, Rouxjeane Venter
F1000Research|September 24, 2020
Rational use of SARS-CoV-2 polymerase chain reaction tests within institutions caring for the vulnerableTom A Yates, Graham S Cooke, Peter MacPherson
Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences|November 6, 2025
The indirect effects of cytomegalovirus infection-mechanisms and consequencesTom A Yates, Helen Payne, Blair L Strang
Open Forum Infectious Diseases|April 21, 2025
Quantifying Potential Immortal Time Bias in Observational Studies in Acute Severe InfectionTom A Yates, Tom Parks, Peter J Dodd
Pageof 5

Showing results (11-20 of 49) with videos related to

Sort By:
Pageof 5
BMJ (Clinical Research Ed.)|April 26, 2012
An alternative set of principles for considerationTom A Yates, Carl J Reynolds
Lancet (London, England)|October 19, 2024
Nutritional supplementation for tuberculosis prevention: the RATIONS trialHannah M Rickman, Tom A Yates
The Journal of Infectious Diseases|January 8, 2026
Re: Estimating the Early Transmission Inhibition of New Treatment Regimens for Drug-Resistant TuberculosisTom A Yates, David A Barr
The Lancet. Infectious Diseases|August 27, 2022
Estimating annual risk of infection with Mycobacterium tuberculosisTom A Yates, Palwasha Y Khan
The Lancet. Microbe|March 18, 2025
Primary efficacy endpoints in phase 3 non-inferiority trials to establish new tuberculosis treatment regimens should only include microbiological outcomesTom A Yates, Daniel J Grint
The Journal of Infectious Diseases|November 13, 2014
HIV infection and the transmission of tuberculosisTom A Yates, Ibrahim Abubakar, Frank Tanser
BMJ (Clinical Research Ed.)|October 10, 2025
Priorities in addressing rifampicin resistant TBTom A Yates, Jessica L Potter, Rouxjeane Venter
F1000Research|September 24, 2020
Rational use of SARS-CoV-2 polymerase chain reaction tests within institutions caring for the vulnerableTom A Yates, Graham S Cooke, Peter MacPherson
Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences|November 6, 2025
The indirect effects of cytomegalovirus infection-mechanisms and consequencesTom A Yates, Helen Payne, Blair L Strang
Open Forum Infectious Diseases|April 21, 2025
Quantifying Potential Immortal Time Bias in Observational Studies in Acute Severe InfectionTom A Yates, Tom Parks, Peter J Dodd
Pageof 5